Try our Advanced Search for more refined results
Life Sciences
-
February 19, 2026
Hims & Hers Buying Eucalyptus For Up To $1.15B
Wellness platform Hims & Hers Health Inc. said Thursday it has agreed to acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion.
-
February 19, 2026
Scientist Must Give Splenda Maker Emails With In-House Attys
A scientist battling a lawsuit by the maker of Splenda over her research linking the artificial sweetener to cancer-causing chemicals must turn over emails with her employer's in-house counsel, a North Carolina magistrate judge ruled, finding they are not protected by privilege.
-
February 19, 2026
Fed. Circ. Won't Revive Corcept's Drug Patent Feud
The Federal Circuit on Thursday declined to revive a case from Corcept Therapeutics Inc. in which it accused Teva Pharmaceuticals USA Inc. of patent infringement over its production of a generic version of the drug Korlym, saying a district judge didn't make a clear error in ruling Corcept hadn't shown any infringement.
-
February 19, 2026
Harvard Docs Get Censored Articles Permanently Restored
The Trump administration agreed to maintain the court-ordered restoration of articles penned by Harvard Medical School researchers that contained references to the LGBTQ+ community after they had previously been scrubbed from a government-hosted website.
-
February 19, 2026
AstraZeneca Prevails In Whistleblower Suit 9th Circ. Revived
An Oregon federal judge tossed a former AstraZeneca sales manager's whistleblower claims that she was fired for accusing a colleague of promoting off-label drugs, in a case that took a trip to the Ninth Circuit and back.
-
February 19, 2026
Trump Orders Weedkiller Glyphosate Production Hike
President Donald Trump issued an executive order late Wednesday aimed at ramping up the production of glyphosate, the active ingredient in the weedkiller Roundup that has been accused of causing cancer in scores of lawsuits, including one on appeal to the U.S. Supreme Court.
-
February 19, 2026
Mylan Investors Ink $60M Deal In Quality Control Suit
Investors in the former Mylan NV have reached a $60 million settlement with the company over claims the drugmaker manipulated quality control measures at a West Virginia facility and lied to shareholders, the investors told a federal court this week.
-
February 19, 2026
BakerHostetler Adds Contaminants Pro From DLA Piper
BakerHostetler announced on Thursday that it has brought a San Francisco-based attorney from DLA Piper onto its product liability and toxic tort and environmental teams, calling him "one of the country's leading emerging contaminants litigators."
-
February 18, 2026
Genetic Testing Co.'s Acquisition Draws Privacy Suit
Healthcare technology company Tempus AI illegally compelled a genetic testing company to disclose its "massive trove" of genetic data through acquisition and then further disclosed affected individuals' private data to other companies without consent, an Illinois mother told a federal court.
-
February 18, 2026
Sandoz's Case Against Amgen Over Enbrel Biosimilar Tossed
A Virginia federal court found that Sandoz Inc. should have brought its claims accusing Amgen of blocking competition for Enbrel in a previous patent dispute over the blockbuster autoimmune disease treatment.
-
February 18, 2026
Axsome Blocks Sleep Disorder Drug Generic Until 2040
Biopharmaceutical business Axsome Therapeutics Inc. has inked a deal to end lawsuits against Alkem Laboratories Ltd. over its generic version of a multimillion-dollar drug meant to help people with excessive daytime sleepiness, keeping the generic off the market for years.
-
February 18, 2026
RFK Jr.-Founded Group Seeks Role In Vaccine Lawsuit
An organization founded by Robert F. Kennedy Jr. asked a Massachusetts federal judge on Wednesday to let it join the U.S. Department of Health and Human Services secretary as a defendant in a lawsuit challenging recent changes to childhood vaccination schedules so the group can pursue counterclaims against the plaintiffs.
-
February 18, 2026
NY Judge Trims Umbilical Cord Blood Co. Investor Suit
A New York federal judge has trimmed a securities class action accusing Global Cord Blood Corp. and others of orchestrating and trying to cover up a scheme in which hundreds of millions of dollars were transferred from Global Cord's cash reserves to its former parent company's founder and other businesses.
-
February 18, 2026
J&J Unit Appeals $442M Catheter Antitrust Loss To 9th Circ.
Johnson & Johnson's Biosense Webster health tech unit urged the Ninth Circuit to overturn a California federal jury's $147 million antitrust verdict — later upped to $442 million — over the company withholding cardiac mapping support to hospitals using third-party reprocessed catheters, saying Innovative Health LLC didn't prove its allegations of unlawful tying.
-
February 18, 2026
FDA Changes Mind, Will Review Moderna MRNA Flu Vaccine
Moderna on Wednesday said that the U.S. Food and Drug Administration has decided to review its application for its influenza vaccine, a week after the agency refused to consider the application for the new experimental vaccine.
-
February 18, 2026
Levi & Korsinsky To Lead Novo Nordisk Investor Class Action
Levi & Korsinsky LLP has been appointed lead counsel in a proposed securities class action accusing Novo Nordisk A/S of misleading investors about its 2025 revenue outlook, after a New Jersey federal judge approved the firm's selection by the investor with the largest financial stake in the case.
-
February 18, 2026
Paul Hastings Adds Cooley Atty As Life Science Deals Leader
Paul Hastings LLP announced Wednesday that it has tapped a former Cooley LLP partner and onetime Merck & Co. attorney to chair its life sciences transactions team.
-
February 17, 2026
Judge Trims Moderna's Defenses In COVID Patent Suit
A federal judge sitting in Delaware on Tuesday ruled that Moderna could not use obviousness to defend itself from patent claims brought by a rival vaccine developer since it already used that as a defense in related Patent Trial and Review Board proceedings, saying that Moderna had offered expert opinions to support a defense that the patents don't sufficiently teach about the claimed invention.
-
February 17, 2026
Judge Rips Drugmakers' Borderline 'Disingenuous' Appeal Bid
A Connecticut federal judge has rejected generic-drug makers' request for a quick appeal of his ruling denying them summary judgment on states' claims they engaged in an "overarching conspiracy" to fix prices, slamming the request for being borderline "disingenuous," mischaracterizing his reasoning and ignoring direct evidence of alleged wrongdoing.
-
February 17, 2026
Union Says Express Scripts Diverted Billions In Kickback Fees
A Chicago plumbers union healthcare fund told an Illinois federal court Tuesday that the nation's largest pharmacy benefit manager, Express Scripts, violated federal criminal law when it used a Switzerland-based company to hide kickbacks it generated by charging drug companies fees for key placement on prescription plan drug lists.
-
February 17, 2026
Squires Ends IPR After ITC Judge Rejects Validity Challenge
U.S. Patent and Trademark Office Director John Squires ended a Patent Trial and Appeal Board review of a Hydrafacial LLC skin treatment patent since the same issue had already been adjudicated in the U.S. International Trade Commission.
-
February 17, 2026
Cohen Milstein To Rep Perrigo Investors In Formula Biz Suit
Cohen Milstein Sellers & Toll PLLC will represent a proposed class of Perrigo Company PLC investors who allege the company failed to disclose critical issues with infant formula operations that it purchased from Nestlé and caused stock prices to drop as the issues came to light.
-
February 17, 2026
McGuireWoods Adds Sidley Private Equity Pro In Los Angeles
McGuireWoods LLP is expanding its transactional team, announcing Tuesday that it is bringing in a Sidley Austin LLP private equity expert as a partner in its Los Angeles office.
-
February 17, 2026
J&J Fights Beasley Allen's Bid To Pause Talc DQ Ruling
A New Jersey state court lacks standing to block an appellate panel's removal of Beasley Allen from representing hundreds of women with ovarian cancer pursuing claims against Johnson & Johnson over talcum powder, the pharmaceutical company has argued in an opposition brief.
-
February 17, 2026
Edwards Sued In Chancery Over $300M Heart Valve Earn-Out
The former shareholders of Valtech Cardio Ltd. have sued the company and its parent Edwards Lifesciences Corp. in the Delaware Chancery Court, accusing the medical device giant of deliberately stalling development of a heart valve repair system to avoid paying up to $300 million in earn-out consideration tied to the 2016 acquisition.
Expert Analysis
-
When Atty Ethics Violations Give Rise To Causes Of Action
Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.
-
What's New In FDA's Latest Cell And Gene Therapy Guidance
New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.
-
Trending At The PTAB: A Potential Barrier To Serial Challenges
New rules proposed by the U.S. Patent and Trademark Office may appear similar to previous rules at first glance, but are actually much broader in how they would limit petitioners' ability to challenge a patent more than once, say attorneys at Finnegan.
-
What's Changing For Cos. In New Calif. Hazardous Waste Plan
While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.
-
Fed. Circ. In September: The Printed Matter Doctrine Expands
The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.
-
Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split
In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.
-
Series
Practicing Stoicism Makes Me A Better Lawyer
Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.
-
Broader Eligibility For AI-Related Patents May Be Coming
A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.
-
Series
The Biz Court Digest: Texas, One Year In
A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.
-
AI Product Safety Insights May Expand Foreseeability
Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.
-
Series
Law School's Missed Lessons: Educating Your Community
Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.
-
Organ Transplant System Reforms Mark Regulatory Overhaul
Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.
-
Adapting To USPTO's Reduction Of Examiner Interview Time
Reported changes to the U.S. Patent and Trademark Office's examiner performance appraisal plan will likely make interviews scarcer throughout the application process, potentially influencing patent allowance rates and increasing the importance of approaching each interview with a clear agenda and well-defined goals, say attorneys at Polsinelli.
-
Federal Grantees May Soon Face More Limitations On Speech
If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.
-
5 Crisis Lawyering Skills For An Age Of Uncertainty
As attorneys increasingly face unprecedented and pervasive situations — from prosecutions of law enforcement officials to executive orders targeting law firms — they must develop several essential competencies of effective crisis lawyering, says Ray Brescia at Albany Law School.